{"id":"NCT02392234","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03","primaryCompletion":"2017-02","completion":"2017-02","firstPosted":"2015-03-18","resultsPosted":"2018-06-12","lastUpdate":"2018-06-12"},"enrollment":248,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"VX-661/Ivacaftor","otherNames":["VX-661+VX-770"]},{"type":"DRUG","name":"Ivacaftor","otherNames":["IVA, VX-770"]},{"type":"DRUG","name":"Placebo matched to VX-661/ ivacaftor","otherNames":[]},{"type":"DRUG","name":"Placebo matched to Ivacaftor","otherNames":[]}],"arms":[{"label":"VX-661/Ivacaftor combination","type":"EXPERIMENTAL"},{"label":"Ivacaftor monotherapy","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of VX-661 in combination with ivacaftor (IVA, VX-770) and IVA monotherapy in participants with Cystic Fibrosis (CF) who are heterozygous for F508del-CFTR allele and a second allele with a CFTR mutation predicted to have residual function.","primaryOutcome":{"measure":"Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Week 4 and Week 8","timeFrame":"Baseline, Week 4 and Week 8 of each treatment period","effectByArm":[{"arm":"Placebo","deltaMin":-0.3,"sd":null},{"arm":"Ivacaftor","deltaMin":4.4,"sd":null},{"arm":"VX-661/IVA","deltaMin":6.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"},{"comp":"OG000 vs OG002","p":"< 0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":93,"countries":["United States","Australia","Belgium","Canada","France","Germany","Israel","Italy","Netherlands","Switzerland","United Kingdom"]},"refs":{"pmids":["37983082","36509366","33331662","29099333"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":162},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Headache","Haemoptysis","Sputum increased"]}}